Scottsdale 6/29/2013 3:00:00 AM
News / Financial Services

ScripsAmerica (SCRC) Inks Strategic Representation Agreement with DPG Distribution for Launch of RapiMed

QualityStocks would like to highlight ScripsAmerica (OTCBB: SCRC). The company provides a strong low cost system of broad base US national marketing, sales, and distribution of generic Rx, branded Rx, OTC, nutraceuticals, and oral delivery OTC pharmaceuticals through mass merchants, super markets, chain drug stores, independent drug stores, hospitals, long term care, HMO’s, home health care, clinics, PBM’s, State and Federal Government (Department of Veterans Affairs, Department of Defense).

In the company’s news,

ScripsAmerica has entered into a two-year agreement with DPG Distribution (DPG) for the exclusive right to purchase, promote, and resell its RapiMed® over-the-counter products throughout North America, initially starting with its children’s pain reliever and fever reducer.

DPG Distribution offers on a global scale the sales, marketing, and distribution services of targeting high-end retail consumer products. The company calls on some of the largest retail chains in the world such as Wal-Mart, Costco, Target, Walgreens, CVS, and ShopRite. The agreement contains a provision whereby its exclusivity is contingent upon DPG meeting designated sales quotas for RapiMed®.

“ScripsAmerica is extremely proud and pleased to announce this agreement, which we believe has tremendous growth implications for our company and its shareholders,” ScripsAmerica’s CEO, Bob Schneiderman, stated in the press release. “DPG Distribution’s network of clients is not only tremendous in size and quality, but it contains some of the world’s largest retailers who are at the pinnacle of our target market.”

The agreement is expected to maximize ScripsAmerica’s national market opportunities for RapiMed® Children’s Pain Reliever and Fever Reducer, which the company anticipates launching in September.

“We expect this development to have a profound and positive impact on the success of RapiMed®’s product launch as well as its ongoing sales and market penetration,” continued Schneiderman.

Gordon Jones, chief operating officer of DPG Distribution, added, “DPG is very excited to represent RapiMed® in the North American market. RapiMed® has the potential to experience great success penetrating the massive market for children’s pain relievers because of its speed, effectiveness, dosing accuracy and safety. Currently, we believe a very large opportunity exists for a new, superior product like RapiMed® to be introduced and capture significant market share. DPG looks forward to a long and profitable partnership with ScripsAmerica.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit  

To connect with QualityStocks via Facebook, please visit

To connect with QualityStocks via Twitter, please visit

Please read FULL disclaimer on the QualityStocks website:   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.